Clinical aspects and management of fibromyalgia syndrome.
- Author:
Yong-Yeow CHONG
1
;
Beng-Yeong NG
Author Information
1. Department of Rheumatology and Immunology, Singapore General Hospital, Singapore. chong.yong.yeow@sgh.com.sg
- Publication Type:Journal Article
- MeSH:
Fibromyalgia;
drug therapy;
etiology;
physiopathology;
Humans;
Rheumatology;
Syndrome
- From:Annals of the Academy of Medicine, Singapore
2009;38(11):967-973
- CountrySingapore
- Language:English
-
Abstract:
Fibromyalgia syndrome (FMS) is a chronic and debilitating musculoskeletal pain disorder of unknown aetiology with usual accompanying features of fatigue, sleep disturbances and stiffness. Its place in medical textbooks was controversial with rheumatologists holding the helm of its management for many years. Over the last decade, abnormalities have been identified at multiple levels in the peripheral, central, and sympathetic nervous systems as well as the hypothalomo-pituitary-adrenal axis stress response system. With the elucidation of these pathways of pain, FMS is known more as a central sensitivity syndrome. This led to tremendous increment in interest in both pharmacological and non-pharmacological treatment of FMS. The United States Food and Drug Administration (FDA) has also successively approved 3 drugs for the management of fibromyalgia--pregabalin, duloxetine and milnacipran. Non-pharmacological modalities showed aerobic exercise, patient education and cognitive behavioural therapy to be most effective. Overall, management of FMS requires a multi-disciplinary approach.
